COMMUNIQUÉS West-GlobeNewswire

The Ensign Group Acquires Real Estate and Expands Operations in Texas
30/04/2026
SAN JUAN CAPISTRANO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior [...]
The Ensign Group Purchases Facilities in Wisconsin
30/04/2026
SAN JUAN CAPISTRANO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
30/04/2026
– Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj ® (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition and increasing uptake in R/R NPM1m [...]
OrthoPediatrics Expands Specialty Bracing Portfolio with TRAXIO Halo Gravity Traction System
30/04/2026
WARSAW, Ind., April 30, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
30/04/2026
Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year IBSRELA Q1 2026 revenue growth of 58% year-over-year to $70.1 million; Reiterating guidance of $410-$430 million Strong financial [...]
Xenon to Report Q1 2026 Financial Results on May 7, 2026
30/04/2026
VANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical [...]
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
30/04/2026
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer’s disease The safety and tolerability profile of AUVELITY in [...]
TME Pharma publishes its annual financial results and annual report
30/04/2026
TME Pharma publishes its annual financial results and annual report Berlin, Germany , April 30, 2026, 20.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in [...]
TME PHARMA PUBLIE SES RÉSULTATS FINANCIERS ANNUELS ET SON RAPPORT ANNUEL
30/04/2026
TME PHARMA PUBLIE SES RÉSULTATS FINANCIERS ANNUELS ET SON RAPPORT ANNUEL Berlin, Allemagne, le 30 avril 2026, 20 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), Une société de biotechnologie en phase [...]
RAPPORT FINANCIER 2025
30/04/2026
RAPPORT FINANCIER 2025 Pièces jointes RAPPORT FINANCIER 2025 RAPPORT FINANCIER 2025
Sofanya Launches Highly Anticipated Sacred Body Oil Just in Time for Mother's Day: 'this isn't about doing more, it's about coming back'
30/04/2026
At the intersection of science and the Divine Feminine, Sofanya creates body care and wellness products that merge cellular nourishment with sacred ritual. Los Angeles, CA, April 30, 2026 (GLOBE NEWSWIRE) -- This Mother [...]
Ocubio Announces Appointment of Jim Mazzo and Dr. Eric Donnenfeld as Strategic Advisors
30/04/2026
MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- Ocubio, a biotechnology company advancing personalized, biologic-based therapies for ocular surface disease, today announced the appointment of James V. Mazzo and Eric D. [...]
KAI Conversations Announces Strategic Partnership with Syneos Health to Advance U.S. Pharmaceutical Commercialization
30/04/2026
AI-Driven Field Insights Drive Pharmaceutical Brand Performance in World’s Largest Market LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- KAI Conversations, an AI-powered conversation intelligence platform purpose-built for [...]
Spineway : First-quarter 2026 revenue
30/04/2026
Ecully, April 30, 2026 – 6:00 p.m. First-quarter 2026 revenue High order volume Slower-than-expected normalization of supply chains 2026: growth trajectory confirmed In thousands of euros 2026 2025 Change as a % Q1 [...]
SPINEWAY :
30/04/2026
Ecully, le 30 avril 2026 – 18h00 Chiffre d’affaires du 1er trimestre 2026 Niveau de commandes élevé Normalisation plus lente que prévue des approvisionnements 2026 : trajectoire de croissance confirmé En milliers d’ [...]
Disclosure of transparency notification from BlackRock, Inc.
30/04/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 April 2026 – 6 PM CET Disclosure of transparency notification from BlackRock, Inc. Pursuant to the Belgian act of 2 May 2007 on the disclosure of [...]
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
30/04/2026
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Dijon, France le 30 avril 2026 (17h45 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , société pharmaceutique spécialisée en phase avancée de développement et [...]
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
30/04/2026
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Dijon, France le 30 avril 2026 (17h45 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , société pharmaceutique spécialisée en phase avancée de développement et [...]
Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554
30/04/2026
Ghent, Belgium – April 30, 2026 – Confo Therapeutics , a leader in the development of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first patients were dosed in a Phase 2a clinical [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum